Half-year report · HY
9987.TEDINET S100X0ID
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.22T | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥2.40T | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.20T | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥17.0bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥17.1bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥18.0bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥38.8bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.0bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥23.2bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥29.0bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥16.2bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥34.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥20.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥16.2bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥20.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥1.17T | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥1.11T | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.22T | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥769.0bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥706.4bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥405.6bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥407.4bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥429.9bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥119.4bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥102.7bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥135.3bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥118.6bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥142.3bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥198.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥25.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥65.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥56.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥7.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥20.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥3.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥15.9bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥35.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥228.09 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥454.58 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥261.16 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 34.5% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.2% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 48
| Segment | Item | Period | Value |
|---|---|---|---|
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥46.5bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥46.5bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3m |
| The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥411m |
| The Healthcare Product Development Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥25.5bn |
| The Healthcare Product Development Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥5.9bn |
| The Healthcare Product Development Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥19.6bn |
| The Healthcare Product Development Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.2bn |
| The Healthcare Related Services Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥20.9bn |
| The Healthcare Related Services Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥12.4bn |
| The Healthcare Related Services Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥8.5bn |
| The Healthcare Related Services Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥521m |
| The Pharmaceutical Distribution Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥1.18T |
| The Pharmaceutical Distribution Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥1.15T |
| The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥26.0bn |
| The Pharmaceutical Distribution Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥14.2bn |
| The Specialty Drug Contract Distribution Business Reportable Segment Memberreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥203.4bn |
| The Specialty Drug Contract Distribution Business Reportable Segment Memberreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥3.5bn |
| The Specialty Drug Contract Distribution Business Reportable Segment Memberreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥200.0bn |
| The Specialty Drug Contract Distribution Business Reportable Segment Memberreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥532m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥1.47T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥1.22T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥254.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥16.8bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥46.7bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥46.7bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥7m |
| The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥126m |
| The Healthcare Product Development Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥26.2bn |
| The Healthcare Product Development Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.9bn |
| The Healthcare Product Development Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥20.2bn |
| The Healthcare Product Development Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.3bn |
| The Healthcare Related Services Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥21.4bn |
| The Healthcare Related Services Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥11.8bn |
| The Healthcare Related Services Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥9.6bn |
| The Healthcare Related Services Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥512m |
| The Pharmaceutical Distribution Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.16T |
| The Pharmaceutical Distribution Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.13T |
| The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥25.6bn |
| The Pharmaceutical Distribution Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥14.5bn |
| The Specialty Drug Contract Distribution Business Reportable Segment Memberreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥137.5bn |
| The Specialty Drug Contract Distribution Business Reportable Segment Memberreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.3bn |
| The Specialty Drug Contract Distribution Business Reportable Segment Memberreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥134.1bn |
| The Specialty Drug Contract Distribution Business Reportable Segment Memberreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥377m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥1.39T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥1.20T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥189.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥16.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 497
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of intangible assets inv cf | InterimDuration | -1428000000 | JPY |
| Purchase of investment securities inv cf | Prior1InterimDuration | -23000000 | JPY |
| Purchase of investment securities inv cf | InterimDuration | -31000000 | JPY |
| Proceeds from sales and redemption of investment securities inv cf | Prior1InterimDuration | 12220000000 | JPY |
| Proceeds from sales and redemption of investment securities inv cf | InterimDuration | 6180000000 | JPY |
| Proceeds from sales of stocks of subsidiaries and affiliates inv cf | Prior1InterimDuration | 2136000000 | JPY |
| Proceeds from sales of stocks of subsidiaries and affiliates inv cf | InterimDuration | － | JPY |
| Investments in subsidiaries and affiliates inv cf | Prior1InterimDuration | -119000000 | JPY |
| Investments in subsidiaries and affiliates inv cf | InterimDuration | -1392000000 | JPY |
| Other net inv cf | Prior1InterimDuration | -227000000 | JPY |
| Other net inv cf | InterimDuration | 132000000 | JPY |
| Net cash provided by used in investment activities | Prior1InterimDuration | 3652000000 | JPY |
| Net cash provided by used in investment activities | InterimDuration | 7447000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1InterimDuration | 19000000 | JPY |
| Proceeds from long term loans payable fin cf | InterimDuration | 19000000 | JPY |
| Repayments of lease obligations fin cf | Prior1InterimDuration | -137000000 | JPY |
| Repayments of lease obligations fin cf | InterimDuration | -128000000 | JPY |
| Purchase of treasury stock fin cf | Prior1InterimDuration | -2000000 | JPY |
| Purchase of treasury stock fin cf | InterimDuration | -12184000000 | JPY |
| Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cf | Prior1InterimDuration | -271000000 | JPY |
| Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cf | InterimDuration | － | JPY |
| Cash dividends paid fin cf | Prior1InterimDuration | -3105000000 | JPY |
| Cash dividends paid fin cf | InterimDuration | -3601000000 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration | -3496000000 | JPY |
| Net cash provided by used in financing activities | InterimDuration | -15895000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1InterimDuration | 10000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | InterimDuration | -25000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | -56430000000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | 16697000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 198745000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 118567000000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 142314000000 | JPY |
| Cash and cash equivalents | InterimInstant | 135264000000 | JPY |
| Salaries and allowances sga | Prior1InterimDuration | 26318000000 | JPY |
| Salaries and allowances sga | InterimDuration | 26213000000 | JPY |
| Provision for bonuses sga | Prior1InterimDuration | 6882000000 | JPY |
| Provision for bonuses sga | InterimDuration | 6715000000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 335000000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 698000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 1129603000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E02780-000TheHealthcareProductDevelopmentBusinessReportableSegmentMember | 5906000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E02780-000TheCommunityHealthcareAndNursingCareSupportBusinessReportableSegmentMember | 46656000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E02780-000TheSpecialtyDrugContractDistributionBusinessReportableSegmentMemberReportableSegmentMember | 3306000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 11849000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 1197323000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 25583000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E02780-000TheHealthcareProductDevelopmentBusinessReportableSegmentMember | 20244000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E02780-000TheCommunityHealthcareAndNursingCareSupportBusinessReportableSegmentMember | 7000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E02780-000TheSpecialtyDrugContractDistributionBusinessReportableSegmentMemberReportableSegmentMember | 134148000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 9554000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |